Compare PRT & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRT | LSTA |
|---|---|---|
| Founded | 2017 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Misc Health and Biotechnology Services |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.3M | 28.9M |
| IPO Year | N/A | 2000 |
| Metric | PRT | LSTA |
|---|---|---|
| Price | $2.07 | $3.75 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 74.2K | 62.4K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | ★ 13.45% | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,283,868.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.78 | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $1.82 | $1.81 |
| 52 Week High | $4.28 | $5.07 |
| Indicator | PRT | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 38.04 | 62.41 |
| Support Level | $1.82 | $3.06 |
| Resistance Level | $3.57 | $4.84 |
| Average True Range (ATR) | 0.13 | 0.15 |
| MACD | 0.03 | 0.07 |
| Stochastic Oscillator | 66.67 | 67.02 |
PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.